These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 18204345)

  • 1. Time to discontinuation and self-discontinuation of olanzapine and risperidone in patients with schizophrenia in a naturalistic outpatient setting.
    Kilzieh N; Todd-Stenberg JA; Kennedy A; Wood AE; Tapp AM
    J Clin Psychopharmacol; 2008 Feb; 28(1):74-7. PubMed ID: 18204345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia.
    Ascher-Svanum H; Zhu B; Faries D; Landbloom R; Swartz M; Swanson J
    BMC Psychiatry; 2006 Feb; 6():8. PubMed ID: 16504026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study.
    Ganguli R; Brar JS; Mahmoud R; Berry SA; Pandina GJ
    BMC Med; 2008 Jun; 6():17. PubMed ID: 18590519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study.
    Haro JM; Novick D; Suarez D; Roca M
    J Psychiatr Res; 2009 Jan; 43(3):265-73. PubMed ID: 18644606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effectiveness of antipsychotics in schizophrenia and related disorders. Results of a naturalistic study].
    Carpiniello B; Mellino G; Pintore S; Puddu L; Pinna F
    Clin Ter; 2011; 162(4):331-41. PubMed ID: 21912821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
    Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Capuano GA; Rosenheck RA; Keefe RS; Miller AL; Belz I; Hsiao JK;
    Am J Psychiatry; 2007 Mar; 164(3):415-27. PubMed ID: 17329466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial.
    Ciudad A; Olivares JM; Bousoño M; Gómez JC; Alvarez E
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Dec; 30(8):1515-22. PubMed ID: 16820255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of different dosing regimens of risperidone and olanzapine in schizophrenia.
    Takeuchi H; Fervaha G; Lee J; Agid O; Remington G
    Eur Neuropsychopharmacol; 2015 Mar; 25(3):295-302. PubMed ID: 25649680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study.
    Perkins DO; Gu H; Weiden PJ; McEvoy JP; Hamer RM; Lieberman JA;
    J Clin Psychiatry; 2008 Jan; 69(1):106-13. PubMed ID: 18312044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the Worldwide Schizophrenia Outpatients Health Outcomes (W-SOHO) study.
    Hong J; Novick D; Brugnoli R; Karagianis J; Dossenbach M; Haro JM
    BMC Psychiatry; 2012 Dec; 12():218. PubMed ID: 23206324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of switching antipsychotic medications.
    Essock SM; Covell NH; Davis SM; Stroup TS; Rosenheck RA; Lieberman JA
    Am J Psychiatry; 2006 Dec; 163(12):2090-5. PubMed ID: 17151159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of atypical antipsychotics in the treatment of schizophrenia in North Staffordshire.
    Hodgson R; Belgamwar R; Al-tawarah Y; MacKenzie G
    Hum Psychopharmacol; 2005 Mar; 20(2):141-7. PubMed ID: 15651052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Schizophrenia Outpatient Health Outcomes (SOHO) study: 3-year results of antipsychotic treatment discontinuation and related clinical factors in Spain.
    Ciudad A; Haro JM; Alonso J; Bousoño M; Suárez D; Novick D; Gilaberte I
    Eur Psychiatry; 2008 Jan; 23(1):1-7. PubMed ID: 18023154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ambulatory use of olanzapine and risperidone: a population-based study on persistence and the use of concomitant therapy in the treatment of schizophrenia.
    Cooper D; Moisan J; Gaudet M; Abdous B; Grégoire JP
    Can J Psychiatry; 2005 Dec; 50(14):901-8. PubMed ID: 16494259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment persistence: a comparison among patients with schizophrenia who were initiated on atypical antipsychotic agents.
    Ren XS; Qian S; Lee AF; Herz L; Miller DR; Kazis LE
    J Clin Pharm Ther; 2006 Feb; 31(1):57-65. PubMed ID: 16476121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis.
    Taylor DM; Wright T; Libretto SE;
    J Clin Psychiatry; 2003 May; 64(5):589-97. PubMed ID: 12755664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia.
    Garman PM; Ried LD; Bengtson MA; Hsu C; McConkey JR
    J Am Pharm Assoc (2003); 2007; 47(3):373-8. PubMed ID: 17510032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
    István S; Agoston T; Tamás T; Zoltán J
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved outcomes following a switch to olanzapine treatment from risperidone treatment in a 1-year naturalistic study of schizophrenia patients in Japan.
    Ye W; Fujikoshi S; Nakahara N; Takahashi M; Ascher-Svanum H; Ohmori T
    Psychiatry Clin Neurosci; 2012 Jun; 66(4):313-21. PubMed ID: 22624736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia.
    Hatta K; Otachi T; Fujita K; Morikawa F; Ito S; Tomiyama H; Abe T; Sudo Y; Takebayashi H; Yamashita T; Katayama S; Nakase R; Shirai Y; Usui C; Nakamura H; Ito H; Hirata T; Sawa Y;
    Schizophr Res; 2014 Sep; 158(1-3):213-22. PubMed ID: 25086659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.